Tue Oct 30, 2007 - Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announced that it has entered the final stages of compound selection for two of the most rapidly growing therapeutic indications, asthma and type 2 diabetes... Forbes Medi-Tech's Press Release -
Blog Archive
-
▼
2007
(88)
-
▼
November
(11)
- Regenetech , Preclinical Studies at Johns Hopkins ...
- Cardium, Phase 2b Excellarate Clinical Study for D...
- DexCom, FDA Approval to Calibrate Its SEVEN Contin...
- DIAMYD, A TYPE 1 DIABETES TRIAL WITH THE EXPERIMEN...
- JDRF and Lilly, Research to Identify Beta Cell Bio...
- Osiris Therapeutics, Phase II Clinical Trial Evalu...
- CV Therapeutics' Anti-Ischemic Agent Ranexa(R), Re...
- Sangamo BioSciences, ZFP Therapeutic Data From Ner...
- Sirtris, Novel Endogenous SIRT1 Activator
- Forbes Medi-Tech, Final Steps in Compound Selecti...
- Nanomix, Exclusive Glucose Detection Licensing Agr...
-
▼
November
(11)
Tuesday, November 6, 2007
Forbes Medi-Tech, Final Steps in Compound Selection for Type 2 Diabetes
Tue Oct 30, 2007 - Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announced that it has entered the final stages of compound selection for two of the most rapidly growing therapeutic indications, asthma and type 2 diabetes... Forbes Medi-Tech's Press Release -
